REG - Verici Dx PLC EKF Diagnostics Hldg - Update re. EKF distribution of shares in Verici Dx

Verici DxAnnouncement

24/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230524:nRSX4215Aa&default-theme=true

RNS Number : 4215A  Verici Dx PLC  24 May 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

Update re. EKF distribution of shares in Verici Dx

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, notes this morning's announcement from EKF Diagnostics
Holdings plc ("EKF") which confirms that EKF has written to certain EKF
Shareholders with regard to the distribution of ordinary Verici shares
previously held by EKF.

 

The full text of the announcement from EKF is reproduced below:

 

Distribution of shares in Verici Dx plc

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that in accordance with the announcement dated 20 June 2022
(the "June 2022 Announcement")(1) in relation to the distribution of certain
shares it held in Verici Dx plc (the "Verici Dividend Shares"), it is today
writing to certain Relevant EKF Shareholders(2) who, at the record date for
the distribution, held their qualifying interest in EKF via CREST (a
Qualifying CREST Account).

 

The letter sets out instructions as to how such persons may elect to receive
all of their Verici Dividend Shares by way of transfer into their Qualifying
CREST Account following the expiry of the lock-up period as described in the
June 2022 Announcement.

 

In the event that no request for transfer into a Qualifying CREST Account is
made, a Relevant EKF Shareholder will automatically receive their Verici
Dividend Shares in certificated form, which may take up to 10 business days
from the expiry of the lock-up period.

 

Notes:

1.
https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862

2.     A Relevant EKF Shareholder is defined in the June 2022 Announcement
as an EKF shareholder who was on the register at the close of business on 24
June 2022, being the record date for the distribution of the Verici Dividend
Shares;  only those investors who held their EKF interests via CREST at that
time are eligible to elect to receive their Verici Dividend Shares into their
Qualifying CREST Account.

3.     If you are the holder of a Qualifying CREST Account and do not
receive any correspondence regarding this matter, please contact LINK as the
Company's receiving agent on the number below.

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Link Group (Registrars)                                  Tel:+44 371 664 0391 or

                                                          shareholderenquiries@linkgroup.co.uk
                                                          (mailto:shareholderenquiries@linkgroup.co.uk)

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 Walbrook PR Limited                                      Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Stephanie Cuthbert /                      Mob: +44 7980 541 893 / +44 7796 794 663 /

 Sam Allen                                                07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical wmanagement for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

Verici Dx's two lead products are Clarava™, a pre-transplant prognosis test
for the risk of early acute rejection, and Tutivia™, a post-transplant test
focused upon acute cellular rejection, including sub-clinical rejection. These
products seek to measure how a patient is likely to respond, and is
responding, to a kidney transplant. These products are underpinned by
extensive patented and published scientific research from the leading Mount
Sinai Medical Center, for which the Company holds an exclusive worldwide
licence.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEEESDEDSESI